fashion -WSS

fashion

author：Wikipedia 2025-10-02 01:12:46 - browse：3831

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Large hospital system sues Multiplan for low

WSS

Will the market for weight loss drugs really reach $100 billion?

Listen: Your guide to Wegovy's blockbuster heart study

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Takeda, Janssen join wearable maker to measure scratching

Organ aging and disease risk measured by new blood test

Wikipedia

fashion

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Where are patients getting their prescriptions for GLP

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

As biotech industry slumps, bioscience job market is upside down

23andMe had bad news about my health. I wish a person had delivered it

J&J to emphasize cancer drugs, stop much of its vaccine research

ChatGPT in medicine: STAT answers readers' burning questions

UnitedHealth’s Optum accused of antitrust violations in California

How to save PrEP access — and even expand it

CDC overhauls leadership of center that led response to Covid

knowledge

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

After John Oliver segment, STAT readers share their opioid

Organ aging and disease risk measured by new blood test

CDC overhauls leadership of center that led response to Covid

The EPA's new lead rule: How one expert crunched the numbers

What don’t we know about an Alzheimer’s drug side effect?

hotspot

explore

hotspot

focus